Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
Publication
, Conference
Khasraw, M; McCowatt, SA; Buyse, ME; Kerstes, Z; Back, M; Kichenadasse, G; Wheeler, H
Published in: Journal of Clinical Oncology
May 20, 2014
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
2050 / 2050
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., McCowatt, S. A., Buyse, M. E., Kerstes, Z., Back, M., Kichenadasse, G., & Wheeler, H. (2014). Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial. In Journal of Clinical Oncology (Vol. 32, pp. 2050–2050). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.2050
Khasraw, Mustafa, Sally Anne McCowatt, Marc E. Buyse, Zoltan Kerstes, Michael Back, Ganessan Kichenadasse, and Helen Wheeler. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.” In Journal of Clinical Oncology, 32:2050–2050. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.2050.
Khasraw M, McCowatt SA, Buyse ME, Kerstes Z, Back M, Kichenadasse G, et al. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 2050–2050.
Khasraw, Mustafa, et al. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 2050–2050. Crossref, doi:10.1200/jco.2014.32.15_suppl.2050.
Khasraw M, McCowatt SA, Buyse ME, Kerstes Z, Back M, Kichenadasse G, Wheeler H. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 2050–2050.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
2050 / 2050
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences